November 2022 in “Journal of Investigative Dermatology” KX-826 is safe and effectively increases hair count in men with hair loss.
1 citations
,
April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences” The mouse models are effective for testing new hair loss treatments.
1 citations
,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
December 2025 in “International Journal of Innovative Technologies in Social Science” New treatments for androgenetic alopecia show promise but need more research for validation.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
March 2026 in “Frontiers in Pharmacology” New treatments for hair loss show promise but need more testing for effectiveness and safety.
August 2025 in “Journal of Cosmetic Dermatology” Interest in new and personalized treatments for hair loss is growing.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
116 citations
,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
3 citations
,
November 1998 in “PubMed”
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
July 2024 in “Reactions Weekly”
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
December 2005 in “Endocrine-related cancer” A woman's adrenal tumor disappeared after treatment with cyproterone acetate.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.